FDA Approves Drug for Pancreatic Cancer in Milestone for Treatment of Deadly Disease
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"FDA Approves Drug for Pancreatic Cancer in Milestone for Treatment of Deadly Disease" is generating significant coverage in the Business category, with 3 articles from 3 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Bloomberg.com, ABC News - Breaking News, Latest News and Videos and Axios. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 83d ago.
Quick answers
Why is "FDA Approves Drug for Pancreatic Cancer in Milestone for Treatment of Deadly Dis" trending?
Because 3 independent news sources published 3 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (15)
- The Race to Develop More Medicines Like the New Pancreatic Cancer Drug The New York Times · 83d ago
- FDA approves landmark pancreatic cancer drug that's shown to improve survival NPR · 83d ago
- Pancreatic cancer drug approved by FDA is "exceptional moment," Boston researcher says CBS News · 83d ago
- Revolution’s pancreatic cancer drug wins speedy FDA approval CNN · 83d ago
- FDA approves breakthrough drug to treat advanced pancreatic cancer ABC11 News · 83d ago
- Opinion WSJ · 83d ago
- U.S. approves breakthrough pancreatic cancer drug, heralding a new era for an intractable disease Scientific American · 83d ago
- FDA approves once-daily pill for deadly cancer after patients' survival rates nearly double Fox News · 83d ago
- Revolution's lifesaving pancreatic cancer drug wins speedy FDA approval Reuters · 83d ago
- FDA Approves New Pancreatic Cancer Drug After Stunning Trial Results Forbes · 83d ago
- FDA approves pancreatic cancer drug that extends patients’ lives The Washington Post · 83d ago
- US approves new treatment for pancreatic cancer Le Monde.fr · 83d ago
- A Breakthrough Pancreatic Cancer Drug Marks a New Era for Treatment Bloomberg.com · 83d ago
- FDA approves breakthrough drug to treat advanced pancreatic cancer ABC News - Breaking News, Latest News and Videos · 83d ago
- A major RAS drug milestone could spur interest in rival assets Axios · 83d ago
Topics
Related trends
Roche Secures First U.S. Approval for New Breast-Cancer Pill
Roche wins FDA approval for its first U.S. oral SERD, giredestrant plus everolimus, for hormone-resistant advanced breast cancer.
Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Novo Nordisk reports Wegovy injection reduced BMI and obesity rates in children as young as six in a clinical trial, expanding the drug's potential pediatric use.
The GLP-1 boom has a dark side
FDA orders new eye-risk warnings on a dozen GLP-1 drugs, including Ozempic and Zepbound, amid reports of vision-threatening events.
Millions of Americans are not taking their GLP-1 drugs as prescribed
Nearly half of U.S. GLP-1 users are altering prescribed dosing, with cost and side effects driving widespread non-adherence.
FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
The United States Food and Drug Administration has rejected Summit Therapeutics and Akeso's lung cancer drug ivonescimab.
Iowa ranks No. 2 for young adult cancer cases
Iowa ranks second nationally for young adult cancer cases as new research links rising rates to early detection of prostate and breast cancers while death rates decline.